GENDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS) MedDRA version: 9.1 Level: LLT Classification code 10061976 Term: Gender identity disorder
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Healthy FtM subjects, who have undergone SR surgery, will be recruited, aged between 18 and 45 years in accordance with the criteria of inclusion and exclusion below. Subjects will be informed about the nature, purpose and objectives of the study and will be requested to sign a written consent to participate in this study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Diabetes Partecipation in other clinical trials Concomitant use of anabolic drugs thrombosis hypertension PA> 140-190 mmhg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: - The role of testosterone versus DHT on muscle metabolism - The role of testosterone versus DHT in the development of muscle strength - The role of testosterone versus DHT in maintaining muscle strength;Secondary Objective: - To evaluate the effects of testosterone and DHT in different physiological functions, such as bone metabolism, body composition, lipid and glucidic profile;Primary end point(s): PRIMARY END- POINTS : - The role of testosterone versus DHT on muscle metabolism - The role of testosterone versus DHT in the development of muscle strength - The role of testosterone versus DHT in maintaining muscle strength | — |
Countries
Italy